Are Proton Pump Inhibitors a Risk Factor for Hypomagnesemia in Patients with  Diabetic Kidney Disease

Abdul Rehman Azeem Dar; Muhammad Hanif Khan Safdar; Usama  Zahid; Muhammad Arif  Sadiq; Muhammad Wasiullah  Khan; Maira  Aleem

doi:10.51253/pafmj.v76i1.11142

Authors

Abdul Rehman Azeem Dar National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Muhammad Hanif Khan Safdar National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Usama Zahid National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Muhammad Arif Sadiq National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Muhammad Wasiullah Khan National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Maira Aleem National University of Medical Sciences (NUMS) Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76i1.11142

Keywords:

Cross-Sectional Study, Diabetic Kidney Disease, Hypomagnesemia, Proton Pump Inhibitors, Serum Magnesium

Abstract

Objective: To compare serum magnesium levels amongst diabetic kidney disease patients using proton pump inhibitors and those not using them.

Study Design: Cross-sectional study.

Place and Duration of Study: Pak-Emirates Military Hospital, Rawalpindi, Pakistan, from May to Jul 2023.

Methodology: Patients with diabetic kidney disease stage 3– 5ND were selected, on regular follow-up in outdoor clinic for at least a month. Exclusion criteria included missing information, use of diuretics or magnesium-containing nutritional supplements or multivitamin tablets, and unwillingness. We recorded data on the use of proton pump inhibitors, including their type, dose, and duration of use. Blood sampling was also done for estimation of serum magnesium, urea, creatinine, sodium, potassium, glycosylated hemoglobin levels and albumin: creatinine levels on spot urinary samples.

Results: This study was done on 94 patients. The mean age of the participants was 62.48 ± 8.32 years. There were 67(77.5%) males and 27(28.4%) females. Proton pump inhibitors were being used by 58(61.7%) patients, and 36(38.3%) were not used.

Conclusion: This study highlights a potential link between hypomagnesemia and proton pump inhibitors in diabetic kidney patients. Care should be exercised by clinicians while dealing with such patients.

Downloads

Download data is not yet available.

References

1. Duan J, Wang C, Liu D, Qiao Y, Pan S, Jiang D, et al. Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in Chinese rural residents: a cross-sectional survey. Sci Rep 2019; 9(1): 1–11. https://doi.org/10.1038/s41598-019-46857-7

2. Arora P, Gupta A, Golzy M. VCU Scholars Compass Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol 2016: 39(3): 204–209. https://doi.org/10.1186/s12882-016-0325-4

3. Misra PS, Alam A, Lipman ML, Nessim SJ. The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: A cross-sectional study. BMC Nephrol 2015; 16: 136. https://doi.org/10.1186/s12882-015-0139-9

4. Pethő ÁG, Tapolyai M, Browne M, Fülöp T. hypomagnesemia as a risk factor and accelerator for vascular aging in diabetes mellitus and chronic kidney disease. Metabolites 2023; 13(2): 306.

https://doi.org/10.3390/metabo13020306

5. Ter Braake AD, Vervloet MG, de Baaij JHF, Hoenderop JGJ. Magnesium to prevent kidney disease-associated vascular calcification: crystal clear? Nephrol Dial Transplant 2022; 37(3): 421-429. https://doi.org/10.1093/ndt/gfaa222

6. Park SH, Lee SH, Lee JS, Shin WY, Gil HW, Yang JO, et al. Changes in serum magnesium concentration after use of a proton pump inhibitor in patients undergoing percutaneous coronary intervention. Kidney Res Clin Pract 2015; 34(2): 98–102.

https://doi.org/10.1016/j.krcp.2015.03.001

7. Danziger J, William JH, Scott DJ, Lee J, Lehman LW, Mark RG, et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 2013; 83(4): 692-699.

https://doi.org/10.1038/ki.2012.452

8. de Francisco ALM, Varas J, Ramos R, Merello JI, Canaud B, Stuard S, et al. Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients. Kidney Int Rep 2018; 3(2): 374-384.

https://doi.org/10.1016/j.ekir.2017.11.001

9. Gommers LMM, Hoenderop JGJ, de Baaij JHF. Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol 2022; 235(4): e13846.

10. https://doi.org/10.1111/apha.13846

11. Liao S, Gan L, Mei Z. Does the use of proton pump inhibitors increase the risk of hypomagnesemia: An updated systematic review and meta-analysis. Medicine. 2019; 98(13): e15011.

https://doi.org/10.1097/md.0000000000015011

12. Alhosaini M, Walter JS, Singh S, Dieter RS, Hsieh A, Leehey DJ. Hypomagnesemia in Hemodialysis Patients: Role of Proton Pump Inhibitors. Am J Nephrol 2014; 39(3): 204–209.

https://doi.org/10.1159/000360011

13. Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie 2021; 76(1): 13–21.

https://doi.org/10.1016/j.therap.2020.06.019

14. Biyik M, Solak Y, Ucar R, Cifci S, Tekis D, Polat I, et al. Hypomagnesemia Among Outpatient Long-Term Proton Pump Inhibitor Users. Am J Ther 2017; 24(1): e52–e55.

https://doi.org/10.1097/mjt.0000000000000154

15. Srinutta T, Chewcharat A, Takkavatakarn K, Praditpornsilpa K, Eiam-Ong S, Jaber BL, et al. Proton pump inhibitors and hypomagnesemia: A meta-analysis of observational studies. Medicine 2019; 98(44): e17788.

https://doi.org/10.1097/md.0000000000017788

16. Veronese N, Pizzol D, Smith L, Dominguez LJ, Barbagallo M. Effect of Magnesium Supplementation on Inflammatory Parameters: A Meta-Analysis of Randomized Controlled Trials. Nutrients 2022; 14(3): 679.

https://doi.org/10.3390/nu14030679

17. Sakaguchi Y. The emerging role of magnesium in CKD. Clin Exp Nephrol 2022; 26(5): 379–384.

https://doi.org/10.1007/s10157-022-02182-4

18. Ashique S, Kumar S, Hussain A, Mishra N, Garg A, Gowda BHJ, et al. A narrative review on the role of magnesium in immune regulation, inflammation, infectious diseases, and cancer. J Health Popul Nutr. 2023; 42(1): 74.

https://doi.org/10.1186/s41043-023-00423-0

19. Abdel-Hameed AR, Ahmed MF, Elsantawy AA, Mohammad MB. Prevalence, risk factors and impact of proteinuria-associated hypomagnesemia in chronic kidney disease patients: cross-sectional study. Egypt J Intern Med 2022; 34(1): 1–8. https://doi.org/10.53350/pjmhs20221611602

20. Lateef Junaid MA, Faraz A, Vaseem M, Salih IMA, Kutbi HAH, Al Julifi MZ, et al. Effect of proton pump inhibitors on Magnesium levels in Type II diabetic patients: a single centre study from Saudi Arabia. Eur Rev Med Pharmacol Sci 2023; 27(3): 1077-1082. https://doi.org/10.26355/eurrev_202302_31204

21. Zaslow SJ, Oliveira-Paula GH, Chen W. Magnesium and Vascular Calcification in Chronic Kidney Disease: Current Insights. Int J Mol Sci 2024; 25(2): 1155. https://doi.org/10.3390/ijms25021155